ERBB2 and neoplasm: This decision was based on robust response rates and duration of response observed across three phase II trials, DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02, confirming the broad anti-tumor activity of this HER2-targeted antibody–drug conjugate (ADC) across diverse cancer types, including gastrointestinal malignancies such as colorectal and biliary tract cancers [103,104,105].